INNOVIVA, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
INNOVIVA, INC. (INVA) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $26.60 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-05
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $26.60M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $26.60M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $26.60M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $26.30M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $26.60M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $26.60M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $26.60M 10-K · filed 2026-02-25 |
| 2025-09-30 | $26.30M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $26.30M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $26.30M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $26.30M 10-K · filed 2025-02-26 |
| 2024-09-30 | $25.80M 10-Q · filed 2024-11-06 |
| 2014-09-30 | $3.50M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $10.90M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $8.10M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $7.10M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |